Use of blinatumomab and CAR T-cell therapy in children with relapsed/refractory leukemia: A case series study

BACKGROUND: The 5-year event-free survival rate for childhood acute lymphoblastic leukemia (ALL) has increased to more than 85%. However, the 5-year overall survival rate in children with relapsed/refractory ALL did not exceed 50%. In the past decade, immunotherapies (such as blinatumomab and chimer...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Songmi, Liu, Aiguo, Wang, Na, Wang, Yaqin, Zhang, Ai, Wang, Li, Yu, Wen, Li, Chunrui, Zhang, Yicheng, Hu, Qun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pediatrics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885096/
https://www.ncbi.nlm.nih.gov/pubmed/36727001
http://dx.doi.org/10.3389/fped.2022.1100404

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885096/
https://www.ncbi.nlm.nih.gov/pubmed/36727001
http://dx.doi.org/10.3389/fped.2022.1100404

Ejemplares similares